Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Magn Reson Med ; 73(3): 1005-14, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24733739

RESUMO

PURPOSE: This study demonstrates how to quantify the tumor blood volume fraction (BVf) using the dynamic Rapid-Steady-State-T1 (RSST1 )-MRI method despite contrast agent (CA) leakage and without arterial input function (AIF) determination. METHODS: For vasculature impermeable to CAs, the BVf is directly quantified from the RSST1 signal amplitude. In case of CA extravasation, we propose a two-compartment model to describe the dynamic RSST1 signal increase. We applied the mathematical model in a pilot-study on a RG2-glioma model to compare extravasation of two Gd-based CAs. The BVf quantification using the mathematical model in a C6-glioma model (n = 8) with the clinical CA Gd-DOTA was validated using a ΔR2 *-steady-state MRI method with an USPIO and by immunohistochemical staining of perfused vessels labeled with Hoechst-33342 dye in the same rats. RESULTS: BVf in tumor and in healthy brain tissues (0.034 ± 0.005 and 0.026 ± 0.004, respectively) derived from the dynamic RSST1 signal were confirmed by ΔR2 *-steady-state MRI (0.036 ± 0.003 and 0.027 ± 0.002, respectively, correlation coefficient rS = 0.74) and by histology (0.036 ± 0.003 and 0.025 ± 0.004 respectively, rS = 0.87). CONCLUSION: Straightforward tumor BVf quantification without AIF determination is demonstrated in presence of CA leakage. The method will facilitate angiogenesis assessment in longitudinal neuro-oncologic studies in particular when monitoring the response to antiangiogenic therapies.


Assuntos
Neoplasias Encefálicas/fisiopatologia , Extravasamento de Materiais Terapêuticos e Diagnósticos/metabolismo , Imageamento por Ressonância Magnética/métodos , Modelos Biológicos , Neovascularização Patológica/fisiopatologia , Animais , Volume Sanguíneo , Determinação do Volume Sanguíneo/métodos , Neoplasias Encefálicas/patologia , Linhagem Celular Tumoral , Simulação por Computador , Meios de Contraste/farmacocinética , Extravasamento de Materiais Terapêuticos e Diagnósticos/etiologia , Extravasamento de Materiais Terapêuticos e Diagnósticos/patologia , Compostos Heterocíclicos/farmacocinética , Interpretação de Imagem Assistida por Computador/métodos , Masculino , Neovascularização Patológica/patologia , Compostos Organometálicos/farmacocinética , Ratos , Ratos Endogâmicos F344
2.
J Neurooncol ; 113(2): 239-49, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23543272

RESUMO

Most of our knowledge regarding glioma cell biology comes from cell culture experiments. For many years the standards for glioma cell culture were the use of cell lines cultured in the presence of serum and 20 % O2. However, in vivo, normoxia in many brain areas is in close to 3 % O2. Hence, in cell culture, the experimental value referred as the norm is hyperoxic compared to any brain physiological value. Likewise, cells in vivo are not usually exposed to serum, and low-passaged glioma neurosphere cultures maintained in serum-free medium is emerging as a new standard. A consequence of changing the experimental normoxic standard from 20 % O2 to the more brain physiological value of 3 % O2, is that a 3 % O2 normoxic reference point enabled a more rigorous characterization of the level of regulation of genes by hypoxia. Among the glioma hypoxia-regulated genes characterized using this approach we found VE-cadherin that is required for blood vessel formation, and filamin B a gene involved in endothelial cell motility. Both VE-cadherin and filamin B were found expressed in pseudopalisades, a glioblastoma pathognomonic structure made of hypoxic migrating cancer cells. These results provide additional clues on the role played by hypoxia in the acquisition of endothelial traits by glioma cells and on the functional links existing between pseudopalisades, hypoxia, and tumor progression.


Assuntos
Antígenos CD/metabolismo , Neoplasias Encefálicas/patologia , Caderinas/metabolismo , Endotélio Vascular/patologia , Filaminas/metabolismo , Glioma/patologia , Hipóxia/patologia , Antígenos CD/genética , Biomarcadores Tumorais/genética , Biomarcadores Tumorais/metabolismo , Western Blotting , Neoplasias Encefálicas/etiologia , Neoplasias Encefálicas/metabolismo , Caderinas/genética , Movimento Celular , Proliferação de Células , Endotélio Vascular/metabolismo , Filaminas/genética , Perfilação da Expressão Gênica , Glioma/etiologia , Glioma/metabolismo , Humanos , Hipóxia/complicações , Técnicas Imunoenzimáticas , Necrose , Análise de Sequência com Séries de Oligonucleotídeos , RNA Mensageiro/genética , Reação em Cadeia da Polimerase em Tempo Real , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Células Tumorais Cultivadas
3.
J Alzheimers Dis ; 42(3): 789-99, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24934545

RESUMO

Epidemiological and experimental studies suggest that 1,25-dihydroxyvitamin D3 (1,25D) plays a neuroprotective role in neurodegenerative diseases including Alzheimer's disease. Most of the experimental data regarding the genes regulated by this hormone in brain cells have been obtained with neuron and glial cells. Pericytes play a critical role in brain function that encompasses their classical function in blood-brain barrier control and maintenance. However, the gene response of brain pericyte to 1,25D remains to be investigated. Analyses of the transcriptomic response of human brain pericytes to 1,25D demonstrate that human brain pericytes in culture respond to 1,25D by regulating genes involved in the control of neuroinflammation. In addition, pericytes respond to the pro-inflammatory cytokines tumor necrosis factor-α and Interferon-γ by inducing the expression of the CYP27B1 gene which is involved in 1,25D synthesis. Taken together, these results suggest that neuroinflammation could trigger the synthesis of 1,25D by brain pericytes, which in turn respond to the hormone by a global anti-inflammatory response. These findings identify brain pericytes as a novel 1,25D-responsive cell type and provide additional evidence for the potential value of vitamin D in the prevention or therapy of Alzheimer's disease and other neurodegenerative/neuropsychiatric diseases associated with an inflammatory component.


Assuntos
Calcitriol/farmacologia , Regulação da Expressão Gênica/efeitos dos fármacos , Pericitos/efeitos dos fármacos , Receptores de Calcitriol/metabolismo , Vitamina D3 24-Hidroxilase/metabolismo , Vitaminas/farmacologia , Encéfalo/citologia , Células Cultivadas , Citocinas/genética , Citocinas/metabolismo , Perfilação da Expressão Gênica , Humanos , Interferon-alfa/farmacologia , RNA Mensageiro/metabolismo , Receptores de Calcitriol/genética , Fator de Necrose Tumoral alfa/farmacologia , Regulação para Cima/efeitos dos fármacos , Vitamina D3 24-Hidroxilase/genética
4.
World J Stem Cells ; 6(2): 134-43, 2014 Apr 26.
Artigo em Inglês | MEDLINE | ID: mdl-24772240

RESUMO

Multipotent mesenchymal stromal cells (MSC), have the potential to differentiate into cells of the mesenchymal lineage and have non-progenitor functions including immunomodulation. The demonstration that MSCs are perivascular cells found in almost all adult tissues raises fascinating perspectives on their role in tissue maintenance and repair. However, some controversies about the physiological role of the perivascular MSCs residing outside the bone marrow and on their therapeutic potential in regenerative medicine exist. In brain, perivascular MSCs like pericytes and adventitial cells, could constitute another stem cell population distinct to the neural stem cell pool. The demonstration of the neuronal potential of MSCs requires stringent criteria including morphological changes, the demonstration of neural biomarkers expression, electrophysiological recordings, and the absence of cell fusion. The recent finding that brain cancer stem cells can transdifferentiate into pericytes is another facet of the plasticity of these cells. It suggests that the perversion of the stem cell potential of pericytes might play an even unsuspected role in cancer formation and tumor progression.

5.
J Neurosci Methods ; 221: 159-65, 2014 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-24126047

RESUMO

The prognosis of glioblastoma remains poor despite significant improvement in cytoreductive surgery, external irradiation and new approach of systemic treatment as antiangiogenic therapy. One of the issues is the low concentration in the infiltrated parenchyma of therapeutic agent administered intravenously mainly due to the blood-brain barrier. An intracerebral injection is advocated to overpass this barrier, this kind of administration need a low flow and continuous injection. The development of sophisticated implanted devices for convection-enhanced delivery is a mandatory step to have a controlled released of a therapeutic agent in glioblastoma treatment. Before testing such a device in a clinical trial a serious preclinical studies are required, in order to test it in realistic conditions we have develop the first induced high grade glioma model in a non-rodent animal: the pig. 21 pigs have been implanted in the parietal lobe with human glioblastoma cell lineage under a chemical immunosuppression by ciclosporine. A MRI follow up was then realized. 15 pigs have been implanted with U87MG, 14 have presented a macroscopic significant tumor, with radiological and anatomapathological characteristics of high grade glioma. 6 pigs were implanted with G6, stem-like cells tumors of glioblastoma, 1 pig develops a macroscopic tumor. This is the first reproducible glioma model in a large animal described, it open the way to preclinical studies to test implanted devices in anatomic realistic conditions, without the ethical issues of a primate use.


Assuntos
Neoplasias Encefálicas/patologia , Linhagem Celular Tumoral/transplante , Modelos Animais de Doenças , Glioma/patologia , Animais , Xenoenxertos , Humanos , Imageamento por Ressonância Magnética , Sus scrofa
7.
J Alzheimers Dis ; 35(3): 553-64, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23455988

RESUMO

Seasonal or chronic vitamin D deficiency and/or insufficiency is highly prevalent in the human population. Receptors for 1,25-dihydroxyvitamin D3, the hormonal metabolite of vitamin D, are found throughout the brain. To provide further information on the role of this hormone on brain function, we analyzed the transcriptomic profiles of mixed neuron-glial cell cultures in response to 1,25-dihydroxyvitamin D3. 1,25-dihydroxyvitamin D3 treatment increases the mRNA levels of 27 genes by at least 1.9 fold. Among them, 17 genes were related to neurodegenerative and psychiatric diseases, or brain morphogenesis. Notably, 10 of these genes encode proteins potentially limiting the progression of Alzheimer's disease. These data provide support for a role of 1,25-dihydroxyvitamin D3 in brain disease prevention. The possible consequences of circannual or chronic vitamin D insufficiencies on a tissue with a low regenerative potential such as the brain should be considered.


Assuntos
Doença de Alzheimer/genética , Doença de Alzheimer/fisiopatologia , Calcitriol/farmacologia , Regulação da Expressão Gênica/efeitos dos fármacos , Doenças Neurodegenerativas/genética , Doenças Neurodegenerativas/fisiopatologia , Neuroglia/efeitos dos fármacos , Neuroglia/fisiologia , RNA Mensageiro/genética , Transcriptoma/efeitos dos fármacos , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/fisiopatologia , Linhagem Celular , Progressão da Doença , Células-Tronco Embrionárias/efeitos dos fármacos , Células-Tronco Embrionárias/fisiologia , Regulação da Expressão Gênica/genética , Humanos , Transtornos Mentais/genética , Transtornos Mentais/fisiopatologia , Camundongos , Neurônios/efeitos dos fármacos , Neurônios/fisiologia , Doença de Parkinson/genética , Doença de Parkinson/fisiopatologia , Receptores de Calcitriol/efeitos dos fármacos , Receptores de Calcitriol/genética , Elemento de Resposta à Vitamina D/efeitos dos fármacos , Elemento de Resposta à Vitamina D/genética
8.
Med Hypotheses ; 78(4): 459-61, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22300485

RESUMO

Gliomas are extremely aggressive and lethal forms of brain cancer. Unlike many other cancer types, glioma cells rarely metastasize. They spread throughout the brain and invasiveness of glioma cells is a major cause of therapeutic failure. In plant ecosystem, biodiversity acts locally as a barrier to ecological invasion. By analogy, we hypothesize that the low cell diversity of differentiated tissues, a counterpart of their functional specificity, opens the way to local cancer cell invasion. Seeding the brain tumor microenvironment with heterogeneous cell populations could be a mean to limit cancer cell invasion by enhancing cell biodiversity.


Assuntos
Neoplasias Encefálicas/fisiopatologia , Microambiente Celular , Glioma/fisiopatologia , Invasividade Neoplásica/fisiopatologia , Diferenciação Celular/fisiologia , Humanos
9.
Clin Diagn Lab Immunol ; 10(5): 934-9, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12965929

RESUMO

The objective of the present work was to set up a routine test adapted to screening for antiendothelial cell antibodies (AECAs) in serum samples with minimal interference from antinuclear antibodies (ANAs) or rheumatoid factors (RFs). We compared the titers of AECAs titrated following two enzyme-linked immunosorbent assays (ELISAs): (i) an ELISA with ethanol-fixed EA.hy926 monolayers as the antigenic substrate and (ii) an ELISA with nucleus-depleted lysates prepared from EA.hy926 cells and normalized for protein (1.0 to 1.7 mg/ml) and DNA (< or =0.1 microg/ml) contents as a surrogate substrate (postnuclear supernatant ELISA [PNS-ELISA]). The AECA titers in 51 serum samples, including 28 samples containing ANAs, were compared. A significantly positive correlation (r = 0.77; P < 0.001) between the two series was shown only for the ANA-negative serum samples. Conversely, ANAs or RFs in samples were shown not to interfere in tests for AECAs by the PNS-ELISA. AECAs recognize their antigenic targets in postnuclear supernatants, which is representative of the endothelial antigenic content, with improvement of the reliability of the assay, a prerequisite to application of the assay for their evaluation in clinical practice.


Assuntos
Autoanticorpos/sangue , Doenças Autoimunes/diagnóstico , Células Endoteliais/imunologia , Ensaio de Imunoadsorção Enzimática , Anticorpos Antinucleares/sangue , Anticorpos Antinucleares/imunologia , Antígenos/imunologia , Doenças Autoimunes/sangue , Linhagem Celular , Reações Cruzadas , Ensaio de Imunoadsorção Enzimática/métodos , Humanos , Reprodutibilidade dos Testes , Fator Reumatoide/sangue , Fator Reumatoide/imunologia , Sensibilidade e Especificidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA